LFSC 📈 F/m Emerald Life Sciences - Overview
Exchange: US • Country: USA • Currency: USD • Type: Etf • • Health
The fund is an actively managed exchange-traded fund ('ETF') and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund's investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Additional Sources for LFSC ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LFSC ETF Overview
| Market Cap in USD | 51m |
| Category | Health |
| IPO / Inception | 2024-10-30 |
LFSC ETF Ratings
| Growth 5y | -34.7% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -2.97 |
| Analysts | - |
| Fair Price Momentum | - |
| Fair Price DCF | - |
LFSC Dividends
No Dividends PaidLFSC Growth Ratios
| Growth Correlation 3m | -13.6% |
| Growth Correlation 12m | -13.6% |
| Growth Correlation 5y | -13.6% |
| CAGR 5y | -5.00% |
| CAGR/Mean DD 5y | -1.08 |
| Sharpe Ratio 12m | -0.72 |
| Alpha | |
| Beta | |
| Volatility | 70.16% |
| Current Volume | 1.8k |
| Average Volume 20d | 1.2k |
What is the price of LFSC stocks?
As of December 22, 2024, the stock is trading at USD 23.75 with a total of 1,800 shares traded.
Over the past week, the price has changed by -5.00%, over one month by -6.01%, over three months by -5.91% and over the past year by -5.91%.
As of December 22, 2024, the stock is trading at USD 23.75 with a total of 1,800 shares traded.
Over the past week, the price has changed by -5.00%, over one month by -6.01%, over three months by -5.91% and over the past year by -5.91%.
Is F/m Emerald Life Sciences a good stock to buy?
Probably not. Based on ValueRay Analyses, F/m Emerald Life Sciences (US:LFSC) is currently (December 2024) not a good stock to buy. It has a ValueRay Growth Rating of -34.70 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LFSC as of December 2024 is . This means that LFSC is currently overvalued and has a potential downside of -100%.
Probably not. Based on ValueRay Analyses, F/m Emerald Life Sciences (US:LFSC) is currently (December 2024) not a good stock to buy. It has a ValueRay Growth Rating of -34.70 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LFSC as of December 2024 is . This means that LFSC is currently overvalued and has a potential downside of -100%.
Is LFSC a buy, sell or hold?
F/m Emerald Life Sciences has no consensus analysts rating.
F/m Emerald Life Sciences has no consensus analysts rating.
What are the forecast for LFSC stock price target?
According to ValueRays Forecast Model, LFSC F/m Emerald Life Sciences will be worth about 0 in December 2025. The stock is currently trading at 23.75. This means that the stock has a potential downside of -100%.
According to ValueRays Forecast Model, LFSC F/m Emerald Life Sciences will be worth about 0 in December 2025. The stock is currently trading at 23.75. This means that the stock has a potential downside of -100%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0 | -100% |